These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36544210)

  • 21. Clinical diagnostic gene expression thyroid testing.
    Steward DL; Kloos RT
    Otolaryngol Clin North Am; 2014 Aug; 47(4):573-93. PubMed ID: 25041959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The association between the ultrasonography TIRADS classification system and surgical pathology among indeterminate thyroid nodules.
    Sahli ZT; Karipineni F; Hang JF; Canner JK; Mathur A; Prescott JD; Sheth S; Ali SZ; Zeiger MA
    Surgery; 2019 Jan; 165(1):69-74. PubMed ID: 30415866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on Molecular Testing for Cytologically Indeterminate Thyroid Nodules.
    Nishino M; Nikiforova M
    Arch Pathol Lab Med; 2018 Apr; 142(4):446-457. PubMed ID: 29336606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular Testing Versus Diagnostic Lobectomy in Bethesda III/IV Thyroid Nodules: A Cost-Effectiveness Analysis.
    Nicholson KJ; Roberts MS; McCoy KL; Carty SE; Yip L
    Thyroid; 2019 Sep; 29(9):1237-1243. PubMed ID: 31407625
    [No Abstract]   [Full Text] [Related]  

  • 25. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.
    Jug RC; Datto MB; Jiang XS
    Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of Gene Expression Classifier Testing of Indeterminate Thyroid Nodules Utilizing a Real Cohort Comparator.
    Shapiro S; Pharaon M; Kellermeyer B
    Otolaryngol Head Neck Surg; 2017 Oct; 157(4):596-601. PubMed ID: 28828911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thyroid nodule molecular profiling: The clinical utility of Afirma Xpression Atlas for nodules with Afirma Genomic Sequencing Classifier-suspicious results.
    Babazadeh NT; Sinclair TJ; Krishnamurthy V; Jin J; Heiden KB; Shin J; Berber E; Siperstein A
    Surgery; 2022 Jan; 171(1):155-159. PubMed ID: 34924179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world Comparison of Afirma GEC and GSC for the Assessment of Cytologically Indeterminate Thyroid Nodules.
    San Martin VT; Lawrence L; Bena J; Madhun NZ; Berber E; Elsheikh TM; Nasr CE
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31665322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.
    Steward DL; Carty SE; Sippel RS; Yang SP; Sosa JA; Sipos JA; Figge JJ; Mandel S; Haugen BR; Burman KD; Baloch ZW; Lloyd RV; Seethala RR; Gooding WE; Chiosea SI; Gomes-Lima C; Ferris RL; Folek JM; Khawaja RA; Kundra P; Loh KS; Marshall CB; Mayson S; McCoy KL; Nga ME; Ngiam KY; Nikiforova MN; Poehls JL; Ringel MD; Yang H; Yip L; Nikiforov YE
    JAMA Oncol; 2019 Feb; 5(2):204-212. PubMed ID: 30419129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach.
    Vriens D; Adang EM; Netea-Maier RT; Smit JW; de Wilt JH; Oyen WJ; de Geus-Oei LF
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3263-74. PubMed ID: 24873995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Effect Modification of Ultrasound Risk Classification on Molecular Testing in Predicting the Risk of Malignancy in Cytologically Indeterminate Thyroid Nodules.
    Hu TX; Nguyen DT; Patel M; Beckett K; Douek M; Masamed R; Rhyu J; Kim J; Tseng CH; Yeh MW; Livhits MJ
    Thyroid; 2022 Aug; 32(8):905-916. PubMed ID: 35611970
    [No Abstract]   [Full Text] [Related]  

  • 32. Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules.
    Endo M; Nabhan F; Porter K; Roll K; Shirley LA; Azaryan I; Tonkovich D; Perlick J; Ryan LE; Khawaja R; Meng S; Phay JE; Ringel MD; Sipos JA
    Thyroid; 2019 Aug; 29(8):1115-1124. PubMed ID: 31154940
    [No Abstract]   [Full Text] [Related]  

  • 33. Longitudinal Assessment of Quality of Life Following Molecular Testing for Indeterminate Thyroid Nodules.
    Schumm MA; Nguyen DT; Kim J; Tseng CH; Chow AY; Shen N; Livhits MJ
    Ann Surg Oncol; 2021 Dec; 28(13):8872-8881. PubMed ID: 34292427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality of Life Following Molecular Marker Testing for Indeterminate Thyroid Nodules.
    Wong CW; Schumm MA; Zhu CY; Tseng CH; Arasu A; Han J; Livhits MJ
    Endocr Pract; 2020 Sep; 26(9):960-966. PubMed ID: 33471700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The value of multi-gene testing in benign or malign diagnosis of thyroid nodules with indeterminate cytology].
    Song YT; Xu GH; Zhu YL; Ma TH; Yu H; Wang TX; Yu WB; Wei W; Zhang B
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Oct; 54(10):764-768. PubMed ID: 31606990
    [No Abstract]   [Full Text] [Related]  

  • 36. Performance of Afirma genomic sequencing classifier vs gene expression classifier in Bethesda category III thyroid nodules: An institutional experience.
    Zhang L; Smola B; Lew M; Pang J; Cantley R; Pantanowitz L; Heider A; Jing X
    Diagn Cytopathol; 2021 Aug; 49(8):921-927. PubMed ID: 34021740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.
    Baca SC; Wong KS; Strickland KC; Heller HT; Kim MI; Barletta JA; Cibas ES; Krane JF; Marqusee E; Angell TE
    Cancer Cytopathol; 2017 May; 125(5):313-322. PubMed ID: 28152275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An update on the status of molecular testing for the indeterminate thyroid nodule and risk stratification of differentiated thyroid cancer.
    Nicholson KJ; Yip L
    Curr Opin Oncol; 2018 Jan; 30(1):8-15. PubMed ID: 29028645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies.
    Yip L; Farris C; Kabaker AS; Hodak SP; Nikiforova MN; McCoy KL; Stang MT; Smith KJ; Nikiforov YE; Carty SE
    J Clin Endocrinol Metab; 2012 Jun; 97(6):1905-12. PubMed ID: 22419727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The first Canadian experience with the Afirma® gene expression classifier test.
    Kay-Rivest E; Tibbo J; Bouhabel S; Tamilia M; Leboeuf R; Forest VI; Hier MP; Savoury L; Payne RJ
    J Otolaryngol Head Neck Surg; 2017 Apr; 46(1):25. PubMed ID: 28372589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.